Alitretinoin
Top View
- WHO Drug Information Vol
- Retinoids (Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tazarotene and Tretinoin) – Update on Teratogenicity and Neuropsychiatric Disorders
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- List of Off-Patent, Off-Exclusivity Drugs Without an Approved Generic
- 1. Benefit Verification and Authorization Support 2. Drug Company Copay Assistance 3
- Dermatological Drugs Market Forecast 2015-2025: Opportunities for Leading Companies
- Vitamin a and Its Derivatives- Retinoic Acid and Retinoid Pharmacology
- Inhibitors of the Menin-Mll Interaction Inhibitoren Der Menin-Mll-Interaktion Inhibiteurs De L’Interaction Ménine-Mll
- MAPI Research Trust, Lyon, France
- Oral Alitretinoin for Patients with Refractory Prurigo
- UC Davis Dermatology Online Journal
- Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin and Tazarotene) ΠUpdate on Teratogenicity and Neuropsychiatric Disorders
- SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
- Supplementary Table 1. Summary of FDA-Approved Anticancer Cytotoxic Drugs at May 2019
- Oncology Agents Not Listed in Seer Book 8
- List of Off-Patent, Off-Exclusivity Drugs Without an Approved Generic
- A Focused Review of Safety Considerations in Cancer Rehabilitation
- Open-Label Pilot Study of Alitretinoin Gel 0.1% in the Treatment of Photoaging